Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Setrusumab
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Jefferies
Deal Size : Undisclosed
Deal Type : Public Offering
Mereo BioPharma Prices $50 Million Direct Offering of American Depository Shares
Details : The net proceeds will be used to fund the clinical advancement of the BPS804 (setrusumab), a monoclonal antibody that is being investigated for the potential treatment of Osteogenesis Imperfecta.
Product Name : BPS-804
Product Type : Antibody
Upfront Cash : Undisclosed
June 14, 2024
Lead Product(s) : Setrusumab
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Jefferies
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Alvelestat
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MPH966 (alvelestat) is an oral drug that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease. It acts to inhibit the neutrophil elastase enzyme and Mereo believes that it has the potential to protect AATD patients from f...
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : Alvelestat
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The multicenter ACTIVATE study is designed to evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics of MPH-313 (etigilimab), Mereo’s proprietary anti-TIGIT antibody, in combination with a PD-1 inhibitor, nivolumab, with dosing every two...
Product Name : MPH-313
Product Type : Antibody
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvelestat
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
Details : Alvelestat (MPH966) is an oral drug that is being researched in people for the treatment of severe Alpha-1 antitrypsin deficiency (AATD) and Bronchiolitis Obliterans Syndrome (BOS).
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2022
Lead Product(s) : Alvelestat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvelestat
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alvelestat (MPH966) is an investigational oral neutrophil elastase inhibitor that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease.
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Alvelestat
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvelestat
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MPH-966 (alvelestat) is an oral drug that is being researched in people with alpha-1 antitrypsin deficiency (AATD) lung disease. Lung disease is the most common impact of AATD in adults.
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2022
Lead Product(s) : Alvelestat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The combination of MPH-313 (etigilimab) and nivolumab has been safe and well tolerated, with an overall response rate (ORR) of 11% and disease control rate (DCR) of 44% with no new safety signals observed to-date.
Product Name : MPH-313
Product Type : Antibody
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment of MPH-313 (etigilimab) in combination with nivolumab has shown preliminary efficacy across multiple tumor types with 2 complete responses, 4 partial responses, and 10 stable disease for an ORR of 15.8% and DCR of 42.1% in heavily pre-treated.
Product Name : MPH-313
Product Type : Antibody
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mereo Reports Interim Data from ACTIVATE Phase 1b/2 Study of Etigilimab
Details : Company promising efficacy, safety, and biomarker data from ACTIVATE aims to enroll approximately 125 patients across seven parallel cohorts of anti-TIGIT antibody MPH-313(etigilimab) in combination with nivolumab for recurrent advanced metastatic solid ...
Product Name : MPH-313
Product Type : Antibody
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : Etigilimab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alvelestat (MPH-966) is a novel, oral small molecule designed to inhibit neutrophil elastase (NE), a neutrophil protease, a key enzyme involved in the destruction of lung tissue.
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : Alvelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable